ACH

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Owens & Minor, Inc. (Note: The input metadata referenced "Accendra Health Inc," but the filing text explicitly identifies the registrant as Owens & Minor, Inc.) for the quarterly period ended March 31, 2005. The company is a distributor of medical and surgical supplies. A significant event during this period was the acquisition of Access Diabetic Supply, LLC, a direct-to-consumer distributor of diabetic supplies, effective January 31, 2005.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 8% year-over-year, driven primarily by higher sales volume to existing customers. The acquisition of Access Diabetic Supply contributed approximately one-tenth of this increase.
• Profitability: Operating earnings rose 8% to $29.6 million. The operating margin remained consistent at 2.5% of revenue. Gross margin improved slightly to 10.5% due to the higher-margin profile of the acquired Access business, partially offset by reduced alternate sourcing of products.
• Cash Flow: Operating cash flow more than doubled to $123.0 million compared to $52.9 million in Q1 2004. This improvement was driven by inventory reductions, improved accounts receivable collections (DSO improved to 24.4 days), and timing of inventory payments.
• Acquisition Impact: The company paid $57.9 million in cash for Access Diabetic Supply. This resulted in a significant increase in goodwill (from $200.5 million to $252.4 million) and a corresponding increase in SG&A expenses as a percentage of revenue (7.9% vs 7.6%).
• Financing Costs: Net interest expense decreased slightly to $3.3 million as the company no longer incurs fees related to a receivables financing facility terminated in May 2004.

Outlook, Risks, and Contingencies

• Capital Expenditures: CapEx increased to $6.2 million in Q1 2005, primarily due to the construction of a new corporate headquarters. Future spending is expected to continue on the headquarters and IT development.
• Liquidity: The company maintains strong liquidity with $74.2 million in cash and $240.7 million available under its revolving credit facility. Management expects available financing to be sufficient for working capital and strategic growth.
• Tax Contingency: The IRS proposed disallowing certain LIFO inventory valuation reductions effective for the 2001 tax year and subsequent years. If unsuccessful in its appeal, the company faces a potential tax deficiency of approximately $41.1 million plus interest of $4.1 million. No reserve has been established for this amount.
• Accounting Changes: The company must adopt SFAS 123R (Share-Based Payment) by January 1, 2006. This is expected to have a material effect on results of operations by requiring fair value recognition of stock-based compensation, though the exact impact depends on future grant levels.
• Forward-Looking Risks: Key risks include healthcare industry cost controls, dependence on large customers, supplier price increases, and the ability to integrate acquisitions successfully.

Investor Verification Checklist

• IRS LIFO Dispute: Verify the status of the appeal regarding the $41.1 million potential tax deficiency and the likelihood of a material cash outflow.
• Access Integration: Monitor the performance of the newly acquired Access Diabetic Supply unit to ensure it delivers the projected higher gross margins without disproportionately increasing SG&A expenses.
• Stock-Based Compensation Impact: Assess the projected expense impact of adopting SFAS 123R in 2006, which will reduce reported net income.
• Capital Allocation: Review the progress and cost overruns associated with the new corporate headquarters construction.
• Working Capital Trends: Confirm if the improved Days Sales Outstanding (24.4 days) and inventory turnover (10.3) are sustainable trends or one-time timing benefits.